Core Points - A shareholder class action lawsuit has been filed against Alto Neuroscience, Inc. alleging that the company made materially false and misleading statements regarding its drug ALTO-100 and its effectiveness in treating Major Depressive Disorder (MDD) [1] - The lawsuit claims that the clinical, regulatory, and commercial prospects of ALTO-100 were overstated, leading to an inflated perception of Alto's business and financial prospects [1] Legal Context - Shareholders who purchased Alto shares between February 2, 2024, and October 22, 2024, and suffered significant losses are encouraged to discuss their legal rights [2] - The deadline to request appointment as lead plaintiff in the case is September 19, 2025 [3]

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Alto Neuroscience, Inc. (“Alto” or the “Company”) (NYSE: ANRO) and certain officers.   The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-06105, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable t ...

NEW YORK, Sept. 2, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Alto Neuroscience, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Alto common stock pursuant and/or ...

NEW YORK, Sept. 1, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto's initial public offering conducted on or about February 2, 2024 (the "IPO"); and/or (ii) securities between February 2, 2024 and October 22, 2024, both dates inclusive (the "Class Period"), of the important September 19, 2025 lead plaintiff deadline.So What: If you purchased Alto securities you may be ent ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Alto Neuroscience, Inc. about the upcoming lead plaintiff deadline for a class action lawsuit related to the company's IPO and subsequent securities transactions [1][2]. Group 1: Class Action Details - Investors who purchased Alto securities during the class period from February 2, 2024, to October 22, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 19, 2025 [3]. - The lawsuit alleges that throughout the class period, defendants made materially false and misleading statements regarding Alto's business and prospects, particularly concerning the effectiveness of ALTO-100 in treating major depressive disorder [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms issuing notices may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, having recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Alto Neuroscience, Inc. common stock during the IPO and the subsequent class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][5]. Group 1: Class Action Details - Investors who purchased Alto securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 19, 2025 [3]. - The lawsuit claims that throughout the class period, defendants made materially false and misleading statements regarding Alto's business and prospects, particularly concerning the effectiveness of ALTO-100 in treating major depressive disorder [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4].

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims against Alto Neuroscience, Inc. for alleged breaches of fiduciary duties by its officers and directors [1] Group 1: Allegations of Misconduct - A federal securities fraud class action complaint has been filed against Alto Neuroscience, alleging that the company made materially false and misleading statements regarding its business and operations [2] - The complaint specifically claims that ALTO-100 was less effective in treating Major Depressive Disorder (MDD) than previously communicated to investors, and that the company's clinical, regulatory, and commercial prospects were overstated [2] - As a result of these alleged misrepresentations, the company's public statements were deemed materially false and misleading at all relevant times [2] Group 2: Actions for Shareholders - Shareholders may pursue changes to the company's corporate governance practices, seek recovery of funds for the company, and request a court-approved incentive award at no cost [3] - Interested parties can join the action through a provided link or by contacting Johnson Fistel, PLLP directly [3] Group 3: About the Law Firm - Johnson Fistel, PLLP is a nationally recognized law firm that represents individual and institutional investors in shareholder derivative and securities class action lawsuits [4]

Core Viewpoint - A class action securities lawsuit has been filed against Alto Neuroscience, Inc. due to alleged securities fraud affecting investors who purchased shares during its initial public offering and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who acquired Alto common stock during its IPO on February 2, 2024, and those who purchased securities between February 2, 2024, and October 22, 2024 [2]. - The complaint alleges that the defendants made false statements regarding the effectiveness of the company's product pipeline, ALTO-100, in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until September 19, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [5].

Core Points - The Gross Law Firm has issued a notice to shareholders of Alto Neuroscience, Inc. regarding a class action lawsuit for those who purchased shares during a specified period [1][3] - The lawsuit alleges that Alto Neuroscience made materially false and misleading statements about its product pipeline, specifically the effectiveness of ALTO-100 in treating major depressive disorder [2] - Shareholders are encouraged to register for the class action by the deadline of September 19, 2025, to potentially be appointed as lead plaintiff [3] Summary by Sections Class Action Details - The class action is on behalf of all persons and entities that purchased Alto common stock during the initial public offering on February 2, 2024, and/or between February 2, 2024, and October 22, 2024 [1] - Registration for the class action is free, and participants will receive updates throughout the case lifecycle [3] Allegations Against Alto Neuroscience - The complaint claims that the effectiveness of ALTO-100 was overstated, leading to inflated clinical, regulatory, and commercial prospects [2] - As a result of these misleading statements, Alto's business and financial prospects were also overstated [2] Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices [4] - The firm seeks recovery for investors who suffered losses due to false or misleading statements that artificially inflated stock prices [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Alto Neuroscience, Inc. during the IPO and the subsequent class period about the upcoming lead plaintiff deadline for a class action lawsuit [1][5]. Group 1: Class Action Details - Investors who purchased Alto securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 19, 2025 [3]. - The lawsuit alleges that defendants made materially false and misleading statements regarding Alto's business and prospects, particularly concerning the effectiveness of ALTO-100 in treating major depressive disorder [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4].